Generally, SGLT2 inhibitors reduce cardiovascular death and HF hospitalization in high-risk patients both with and without diabetes, improving outcomes in HF with reduced and preserved ejection fraction through hemodynamic, anti-inflammatory, and metabolic benefits beyond glucose lowering (140). This evidence concerns the gene SLC5A2 and diabetes mellitus.